Jobs could be lost amid plans for NHS mergers
Jobs could be lost amid plans for health authorities in Gloucestershire to be merged with those in neighbouring counties.
A national blueprint has been published setting out changes to the function of Integrated Care Boards (ICB) which would see responsibilities go to neighbourhood providers and NHS regions.
Gloucestershire currently has its own ICB but health bosses were told on 8 May that this could soon change.
Gloucestershire Hospitals NHS Trust chief executive Kevin McNamara said a significant reductions of non-clinical staff was expected.
Central government wants to reduce the running costs of ICBs by around 50 per cent and cut non-clinical leadership by half, a Gloucestershire Hospitals NHS Trust board was told at a meeting last week.
Mr McNamara said: "There will be human impact. We are working closely with ICB and Gloucestershire Health and Care NHS Foundation Trust colleagues to work our way through this."
He said there was a vacancy freeze for non-clinical roles in the organisation unless they had a direct bearing on patient or staff safety or were business critical, reports the Local Democracy Reporting Service.
"It's pretty fast moving," he said.
He explained that over the next few months more would be known as discussions about how ICBs should be clustered was ongoing.
More news stories for Gloucestershire
Listen to the latest news for Gloucestershire
NHS England has published guidance showing the roles and responsibilities of health authorities and ICBs.
Mr McNamara said the NHS could be more efficient and said in Gloucestershire some of the corporate back office functions were triplicated.
The NHS Gloucestershire Integrated Care Board said in a statement that any structural changes to the ICBs would not affect the current day to day provision of health services.
It said the board would continue to have a critical role as strategic commissioners working to improve health, reduce inequalities and improve healthcare access.
A spokesperson added: "In order to meet our more focused strategic commissioning role and the requirement to reduce our organisational costs, the ICB footprint is likely to be larger in the future, but it will be crucial to retain strong 'place' based arrangements and partnerships at a local level."
Follow BBC Gloucestershire on Facebook, X and Instagram. Send your story ideas to us on email or via WhatsApp on 0800 313 4630.
'Blood test delays' as workers continue pay protest
NHS phlebotomists six weeks into strikes over pay
Maternity services rated 'unsafe' by inspectors
Local Democracy Reporting Service
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
HealthX Intelligence Conference 2025: The Premier Event for Healthcare Professionals Looking to Stay at the Cutting Edge of Technology (London, United Kingdom - September 17-18, 2025)
Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "HealthX Intelligence 2025" conference has been added to offering. The HealthX Intelligence 2025 conference is the premier event for healthcare professionals looking to stay at the cutting edge of technology. This two-day event features keynote speakers from top technology companies, hospitals & healthcare providers, pharmaceutical companies, investors, government agencies, and tech start-ups and the event will provide attendees with an immersive experience that explores how artificial intelligence, automation, machine learning and data analytics can be used to revolutionize healthcare delivery and patient care. From emerging technologies to successful implementations, this unique conference provides valuable insights into current trends in healthcare innovation. Participants will have the opportunity to explore various case studies, present their research findings, interact with experts in the field, and develop new collaborations. Additionally, they can learn about emerging technologies that could potentially revolutionize healthcare delivery systems in the years ahead. With HealthX Intelligence 2025, you'll have the knowledge and tools to ensure that your organization is well-prepared for what lies ahead in the world of healthcare. Join us to experience the possibilities for Healthcare Innovation in 2025 and beyond. KEY DISCUSSIONS WE'LL BE EXPLORING Digital Health Adoption & Implementation Strategies Artificial intelligence (AI) in health systems Machine learning and deep learning applications Health Data analytics and predictive modelling Utilizing Big Data for More Effective Population Health Management Cloud Technologies Automation and robotics in healthcare delivery Intelligent medical devices and wearable technology Electronic health records (EHR) and healthcare information systems Telemedicine and remote patient monitoring Clinical decision support systems Natural language processing (NLP) and voice recognition in healthcare Health data privacy and security in the age of automation Patient engagement and personalized medicine Healthcare process optimization and workflow automation Internet of Medical Things (IoMT) and connected healthcare Blockchain applications in healthcare Integrated Care Platforms Ethical and regulatory considerations in healthcare automation Digital Leadership Impact of Technology in Home Healthcare Who Should Attend: Healthcare Professionals Technology Experts Healthcare Providers Investors & Government Agencies Tech Startups Researchers in Artificial Intelligence and Automation Data Analysts & Analytics Specialists Clinical Managers & Administrators Wearable Technology Developers IT Professionals Working With Big Data Robotics Engineers Medical Device Manufacturers Entrepreneurs Pursuing Innovative Solutions in the Healthcare Industry For more information about this conference visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
World must ‘start screening for prostate cancer to stop men being left behind'
Every country should have a strategy for tackling prostate cancer with dedicated screening programs for men over 50, a leading health charity has said. Global Action on Men's Health, the leading international charity for men's health, is calling for prostate cancer – now the third most common cancer worldwide – to be dramatically elevated on the health agenda. On Monday it will launch a campaign to encourage all countries with adequate resources, including the UK, to launch national screening for the disease in a bid to cut unnecessary deaths. It will also call for the World Health Organization (WHO) to introduce a Global Prostate Cancer Initiative which 'covers every stage of the prostate cancer pathway from prevention to palliative care'. Prostate cancer is now the most frequently diagnosed cancer in men in 112 countries and the leading cause of cancer death among men in 48 countries. In England, it is now the most common cancer, killing some 12,000 men every year, according to Prostate Cancer UK. Writing in today's Telegraph, Peter Baker, the director of Global Action on Men's Health, said that men were being short-changed when it comes to healthcare. 'Men's health has been neglected for far too long with devastating consequences,' he writes. 'Globally, men's life expectancy lags five years behind women's. Men are significantly more likely to develop and die from cancer, heart disease, diabetes and tuberculosis. They are also at much greater risk of dying from suicide or an accident on the roads or at work.' Mr Baker calls for reform across health care systems – ensuring men have better access to GPs, for instance – and believes that a focus on prostate cancer is a good place to start. Rapid advances in screening technologies now mean that developed nations should soon be able to launch screening programs that will cut death rates by a third or more and reduce the dramatic social inequalities associated with the disease. Men with a family history of prostate cancer run a significantly higher genetic risk of developing prostate cancer, as do black men. Men from lower socioeconomic backgrounds are also much harder hit, due to a combination of poor health literacy and access to healthcare. The European Commission recently recommended introducing national prostate cancer screening across all 27 member states of the European Union, and already countries including Sweden and Norway have either launched or are on the brink of launching national screening programs. While blood tests for prostate cancer, known as prostate-specific antigen tests (PSA), have been available for many years, they throw up a large number of false positives. This in turn led to many unnecessary prostate removals and biopsies being performed, meaning the risks outweighed the benefits of running national screening programmes. But now, with the advent of more specific blood tests and high resolution MRI scans, which allow for much more accurate biopsies, the balance has changed, with several high quality studies showing the benefit of screening. The largest of these studies was the European Randomised Study of Screening for Prostate Cancer (ERSPC), which included over 182,000 men and showed a 20 per cent reduction in prostate cancer mortality among those screened. Another study in Gothenburg, Sweden, found that after 18 years of follow-up, men in the screening group were 35 per cent less likely to die from prostate cancer than men who were not screened. Men who started screening at age 55-59 were 53 per cent less likely to die. Professor Jonas Hugosson, a urologist at University of Gothenburg in Sweden who led the Swedish study, said he expected national screening for prostate cancer to be rolled out across most western European nations in the next few years. In Sweden a move to nationwide screening was already progressing and in Norway he expected a national screening program to be announced shortly, he said. However, just as with the roll out of breast cancer screening more than three decades ago, it would take most countries many years to gear up. 'In my view, we have quite a new situation today, and I think it's time for the health authorities to take a new standpoint,' he said. 'I'm quite sure about that and we will see screening come all over Europe during the coming years, but it takes 10 years to build up, at least.' The NHS in England does not have a dedicated men's health strategy but one has been promised by the end of the year by the new Health Secretary, Wes Streeting. Although the new strategy is unlikely to include the imminent launch of a national screening program for prostate cancer – the UK currently does not have the MRI machines and trained staff needed to launch one – it may include screening for high risk groups. These include black men, who have double the normal risk, and men with a family history of prostate and related cancers – including breast and ovarian cancer on the female side. In October last year, six-time Olympic cycling champion Sir Chris Hoy, 49, revealed that he had terminal prostate cancer. Both his father and grandfather had the disease but his was not caught by early testing, sparking an outcry. 'The rapid rise in prostate cancer cases is not just alarming, it is also unnecessary and therefore unacceptable,' said Global Action on Men's Health. 'Prostate cancer is currently inadequately addressed in global and national cancer policies'. In addition to national testing where possible, the charity is calling for the WHO to support a new Global Prostate Cancer Initiative covering 10 areas. These include governments being urged to introduce national cancer plans which specifically address prostate cancer with clear performance indicators, education programmes to raise awareness and tackle stigma, and investments in research, infrastructure, workforce development and treatments for prostate cancer. The WHO does not currently have a programme that focuses specifically on prostate cancer but 'integrates' it to its wider program for tackling cancer more generally. Cervical cancer, in contrast, has a dedicated programme dedicated to its global eradication but that is because the HPV vaccine makes it possible to wipe out the disease completely. Dr André Ilbawi, technical lead for cancer control at the WHO, welcomed the prostate campaign launched by Global Action on Men's Health, and said the disease was moving up the WHO's agenda. The organisation had just five countries involved in its cancer programme in 2015 to but has 100 today. 'We see prostate cancer as a priority and, in 2023, elevated it in our guidance because it can be treated,' said Dr IIbawi. 'If treatment is available, survival is extremely high. And if treatments are not available, those men will die. 'We agree that prostate cancer should be seen in the cancer agenda as high impact, cost-effective and meeting community needs'. Protect yourself and your family by learning more about Global Health Security Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Yahoo
2 hours ago
- Yahoo
Healthcare firm Totally collapses but divisions sold
Former NHS 111 urgent care provider Totally has collapsed into administration, but said a deal to sell its main divisions will see the 'uninterrupted provision' of all its services. The Derby-based healthcare firm – which lost the NHS 111 support contract in February this year – has appointed Ernst & Young partners Tim Vance and Sam Woodward as joint administrators after failing to secure bids or strategic investors for the entire firm. It said that following the appointment, the sale of its selective care and corporate wellbeing subsidiaries, as well as the urgent care division, was completed to rival PHL Group. 'This transaction sees the continued and uninterrupted provision of all services previously delivered by the group,' Totally said. Totally employed more than 1,400 employees, according to its 2023-2024 annual report. The group added: 'PHL Group will make separate announcements shortly, including communication with the customers, suppliers and employees of the elective care and urgent care divisions, and the corporate wellbeing business, which are all continuing to provide all services as normal following the transaction.' The company's failure comes after a difficult past year, with the firm losing the NHS 111 contract worth £13 million and then revealing last month it was facing a potential medical negligence claim related to an incident in January 2018. At the time, it warned the size of the liability for the claim could be more than the £10 million claim limit on its insurance policy. It launched a strategic review to look at options, including the sale of subsidiaries 'receiving strategic investment or undertaking some other form of comparable corporate action'. Shares in the firm plummeted at the time. On June 6, it announced its intention to appoint administrators after the review had failed to see any 'solvent' offers for parent firm Totally and suspended its shares from trading on London's junior Aim market. PHL – the buyer of its trading divisions – was launched in 2009 and runs services in the UK and overseas, including integrated urgent care, urgent treatment centres, surgical insourcing, custody healthcare, ADHD services and general practice. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
